Viking Therapeutics, Inc.

Welcome to the Viking Therapeutics 2022 Second Quarter Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press the star key followed by one on your touch-tone phone. If anyone has difficulty hearing the conference, please press star then zero for operator assistance. As a reminder, this conference call is being recorded today July 27, 2022. I would now like to turn the conference over to Vikings Manager of Investor Relations, Stephanie Diaz. Please go ahead, Stephanie.

Hello, and thank you all for participating in today's call. Joining me today is Brian Leon, Vikings President and CEO, and Greg Zante, Vikings CFO. Before we begin, I'd like to caution that comments made during this conference call today, July 27, 2022, will contain forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements about Vikings' expectations regarding its development activities, timelines, and milestones. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and adversely, and reported results should not be considered as an indication of future performance. These forward-looking statements speak only as of today's date and the company undertakes no obligation to revise or update any statement made today. I encourage you to review all of the company's filings with the Securities and Exchange Commission concerning these and other matters. I'll now turn the call over to Brian Lian for his initial comments.

Thanks, Stephanie, and thanks to everyone dialed in by phone or listening on the webcast. Today, we'll review our financial results for the second quarter of 2022 and provide an update on recent progress with our pipeline programs and operations. During the second quarter, we continued to advance each of our three clinical programs. With respect to our lead compound, VK2809, we continued enrollment in the Phase IIb VOYAGE study, targeting patients with biopsy-confirmed NASH and fibrosis, and we expect to complete enrollment in this study in the second half of the year. We also continued to enroll subjects in a Phase I trial of our newest clinical program, evaluating VK2735, a dual agonist of the glucagon-like peptide 1, and glucose-dependent insulinotropic polypeptide receptors. We're eager to evaluate the results from this study, and we expect to report the initial data later this year. Finally, with respect to our second novel thyroid hormone receptor beta agonist, BK0214, for the treatment of X-linked adrenal leukodystrophy, as discussed on our last call, the FDA earlier this year had requested the completion of an in vivo study prior to continued dosing of patients in a Phase 1b study of this compound. During the second quarter, we successfully completed the requested study, submitted the results to the FDA, and were recently informed that the trial may proceed as planned. We're currently in the process of resuming the study and look forward to reporting the results in 2023. I'll provide further detail on our operations and development activities after we review our second quarter financial results. For that, I'll turn the call over to Greg Zanti Vikings Chief Financial Officer.